REGENXBIO CMO exercises options, sells 2,161 shares
REGENXBIO Inc. Chief Medical Officer Steve Pakola exercised stock options and sold shares in a planned transaction.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
4
Rhea-AI Filing Summary
REGENXBIO Inc. Chief Medical Officer Steve Pakola exercised stock options and sold shares in a planned transaction. On this Form 4, he exercised options for 2,161 shares of common stock at $7.86 per share, then sold 2,161 shares in an open-market sale at $13.64 per share.
These transactions were made pursuant to a Rule 10b5-1 trading plan, indicating they were pre-scheduled. After the sale, he directly holds 213,009 shares of common stock and 64,812 stock options that remain exercisable.
Insider Trade Summary 10b5-1
Exercise and Sale: 2,161 shares ($12K approx. pre-tax spread)
Exercise and Sale
3 txns
Insider
PAKOLA STEVE
Role
Chief Medical Officer
Sold
2,161 shs ($29K)
Approx. gross sale proceeds
$29K
Approx. exercise cost
$17K
Approx. pre-tax spread
$12K
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Stock Options (Right to Buy) | 2,161 | $0.00 | $0.00 |
| Exercise | Common Stock | 2,161 | $7.86 | $17K |
| Sale | Common Stock | 2,161 | $13.64 | $29K |
Holdings After Transaction:
Stock Options (Right to Buy) — 64,812 contracts (Direct);
Common Stock — 213,009 shares (Direct)
Footnotes (2)
- F1. This transaction was effected pursuant to a Rule 10b5-1 trading plan.
- F2. The previously granted option, representing a right to purchase a total of 103,698 shares, became exercisable as follows: 25% of the shares subject to this option vested on January 2, 2026, and the balance vests in equal monthly installments over the 36 months thereafter while the optionee provides continuous service to the Issuer.
Key Figures
Shares sold: 2,161 shares
Sale price: $13.64 per share
Option exercise price: $7.86 per share
+3 more
6 metrics
Shares sold
2,161 shares
Open-market sale of common stock
Sale price
$13.64 per share
Price for 2,161 common shares sold
Option exercise price
$7.86 per share
Exercise price for 2,161 stock options
Shares held after
213,009 shares
Common stock directly owned post-transaction
Options remaining
64,812 options
Stock options outstanding after exercise
Original option grant size
103,698 shares
Total shares subject to previously granted option
Key Terms
Rule 10b5-1 trading plan, Stock Options (Right to Buy), Exercise or conversion of derivative security, open-market sale, +1 more
5 terms
Rule 10b5-1 trading plan regulatory
"This transaction was effected pursuant to a Rule 10b5-1 trading plan."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Options (Right to Buy) financial
"Stock Options (Right to Buy) with an expiration date of 2035-01-02"
Exercise or conversion of derivative security financial
"transaction_code_description: Exercise or conversion of derivative security"
open-market sale financial
"transaction_action: open-market sale of common stock"
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
vesting financial
"the balance vests in equal monthly installments over the 36 months thereafter"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider transaction did REGENXBIO (RGNX) report for Steve Pakola?
REGENXBIO reported that Chief Medical Officer Steve Pakola exercised stock options for 2,161 shares and sold 2,161 common shares. The Form 4 shows an option exercise followed by an open-market sale on the same date as part of routine equity activity.
What options did Steve Pakola exercise in this REGENXBIO (RGNX) Form 4?
He exercised stock options covering 2,161 shares of REGENXBIO common stock at a conversion or exercise price of $7.86 per share. These options are part of a previously granted award that vests over time, as described in the filing’s footnotes.
Was the REGENXBIO (RGNX) insider sale by Steve Pakola under a Rule 10b5-1 plan?
Yes. The footnotes state the transaction was effected pursuant to a Rule 10b5-1 trading plan. Such plans pre-schedule trades in advance, making the timing more routine and less indicative of short-term views on the company’s prospects.
What is the vesting schedule for Steve Pakola’s REGENXBIO (RGNX) options mentioned in the Form 4?
The previously granted option for 103,698 shares vested 25% on January 2, 2026, with the remaining shares vesting in equal monthly installments over 36 months. Continued vesting depends on his ongoing service to REGENXBIO, according to the filing footnote.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates